154 related articles for article (PubMed ID: 17264798)
1. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.
Tanimoto K; Kaneyasu M; Shimokuni T; Hiyama K; Nishiyama M
Pharmacogenet Genomics; 2007 Jan; 17(1):1-10. PubMed ID: 17264798
[TBL] [Abstract][Full Text] [Related]
2. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
3. Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes.
Fukami T; Nakajima M; Maruichi T; Takahashi S; Takamiya M; Aoki Y; McLeod HL; Yokoi T
Pharmacogenet Genomics; 2008 Oct; 18(10):911-20. PubMed ID: 18794728
[TBL] [Abstract][Full Text] [Related]
4. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
5. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF
Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373
[TBL] [Abstract][Full Text] [Related]
6. Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes.
Hosokawa M; Furihata T; Yaginuma Y; Yamamoto N; Watanabe N; Tsukada E; Ohhata Y; Kobayashi K; Satoh T; Chiba K
Drug Metab Pharmacokinet; 2008; 23(1):73-84. PubMed ID: 18305377
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-prodrug systems: carboxylesterase/CPT-11.
Danks MK; Potter PM
Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
[No Abstract] [Full Text] [Related]
8. A discriminative analytical method for detection of CES1A1 and CES1A2/CES1A3 genetic variants.
Zhu HJ; Brinda B; Froehlich TE; Markowitz JS
Pharmacogenet Genomics; 2012 Mar; 22(3):215-8. PubMed ID: 22237548
[TBL] [Abstract][Full Text] [Related]
9. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.
Kojima A; Hackett NR; Crystal RG
Cancer Res; 1998 Oct; 58(19):4368-74. PubMed ID: 9766666
[TBL] [Abstract][Full Text] [Related]
10. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM
Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229
[TBL] [Abstract][Full Text] [Related]
11. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Kojima A; Hackett NR; Ohwada A; Crystal RG
J Clin Invest; 1998 Apr; 101(8):1789-96. PubMed ID: 9541511
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
[TBL] [Abstract][Full Text] [Related]
13. Novel procedure with improved resolution and specificity for amplification and differentiation of variants of the gene encoding carboxylesterase 1.
Bjerre D; Rasmussen HB;
Pharmacogenet Genomics; 2017 Apr; 27(4):155-158. PubMed ID: 28146010
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less toxic dose of irinotecan.
Uchino J; Takayama K; Harada A; Sone T; Harada T; Curiel DT; Kuroki M; Nakanishi Y
Cancer Gene Ther; 2008 Feb; 15(2):94-100. PubMed ID: 18157147
[TBL] [Abstract][Full Text] [Related]
15. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
16. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
17. Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations.
Rasmussen HB; Madsen MB; Lyauk YK; Hansen PR; Hughes T;
Drug Metab Pers Ther; 2017 Sep; 32(3):163-168. PubMed ID: 28803225
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11.
Oosterhoff D; Overmeer RM; de Graaf M; van der Meulen IH; Giaccone G; van Beusechem VW; Haisma HJ; Pinedo HM; Gerritsen WR
Br J Cancer; 2005 Mar; 92(5):882-7. PubMed ID: 15756257
[TBL] [Abstract][Full Text] [Related]
19. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.
Merali Z; Ross S; Paré G
Drug Metabol Drug Interact; 2014; 29(3):143-51. PubMed ID: 24988246
[TBL] [Abstract][Full Text] [Related]
20. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
